Toxicological and metabolic considerations for histone deacetylase inhibitors

Romidepsin for Cutaneous T-cell Lymphoma

(2012) H. M. Prince et al.   CLINICAL CANCER RESEARCH

A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors

(2012) Akira Fukutomi et al.   INVESTIGATIONAL NEW DRUGS

Vorinostat with sustained exposure and high solubility in poly(ethylene glycol)‐b‐poly(dl‐lactic acid) micelle nanocarriers: Characterization and effects on pharmacokinetics in rat serum and urine

(2012) Elham A. Mohamed et al.   JOURNAL OF PHARMACEUTICAL SCIENCES

Phase II trial of the histone deacetylase inhibitor romidepsin in patients with recurrent/metastatic head and neck cancer

(2012) Missak Haigentz et al.   ORAL ONCOLOGY

Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome

(2011) Sophie Dimicoli et al.   AMERICAN JOURNAL OF HEMATOLOGY

Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS)

(2011) Amanda Cashen et al.   ANNALS OF HEMATOLOGY

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

(2011) R. L. Piekarz et al.   BLOOD

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia

(2011) M. J. Bishton et al.   BLOOD

The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer

(2011) Geoffrey I. Shapiro et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Effect of ketoconazole-mediated CYP3A4 inhibition on clinical pharmacokinetics of panobinostat (LBH589), an orally active histone deacetylase inhibitor

(2011) Paul Hamberg et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I dose-escalating study of panobinostat (LBH589) Administered intravenously to Japanese patients with advanced solid tumors

(2011) Sachi Morita et al.   INVESTIGATIONAL NEW DRUGS

Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma

(2011) Mark Kirschbaum et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial Tumors

(2011) Giuseppe Giaccone et al.   JOURNAL OF CLINICAL ONCOLOGY

Optimization of the in Vitro Cardiac Safety of Hydroxamate-Based Histone Deacetylase Inhibitors

(2011) Michael D. Shultz et al.   JOURNAL OF MEDICINAL CHEMISTRY

Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial

(2011) Anas Younes et al.   LANCET ONCOLOGY

Unknown

(2011) Antonio Furlan et al.   MOLECULAR MEDICINE

Histone Deacetylase Inhibitors: Emerging Mechanisms of Resistance

(2011) Robert W. Robey et al.   MOLECULAR PHARMACEUTICS

Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes

(2011) Marcus Bantscheff et al.   NATURE BIOTECHNOLOGY

A phase I/II trial of the histone deacetylase inhibitor romidepsin for adults with recurrent malignant glioma: North American Brain Tumor Consortium Study 03-03

(2011) Fabio M. Iwamoto et al.   NEURO-ONCOLOGY

Impact of UDP-gluconoryltransferase 2B17 genotype on vorinostat metabolism and clinical outcomes in Asian women with breast cancer

(2011) Nan-Soon Wong et al.   Pharmacogenetics and Genomics

Vorinostat: A novel therapy for the treatment of cutaneous T-cell lymphoma: Figure 1

(2010) Shannon A. Kavanaugh et al.   AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY

Histone deacetylase inhibitors: A chemical genetics approach to understanding cellular functions

(2010) Paul A. Marks   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

(2010) Ruben Niesvizky et al.   CANCER

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)

(2010) N. L. Steele et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours

(2010) Helen J. Mackay et al.   EUROPEAN JOURNAL OF CANCER

Vorinostat in acute myeloid leukemia and myelodysplastic syndromes

(2010) Thomas Prebet et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase I Study of Vorinostat in Patients With Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

(2010) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY

Final Results From a Multicenter, International, Pivotal Study of Romidepsin in Refractory Cutaneous T-Cell Lymphoma

(2010) Sean J. Whittaker et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma

(2010) Suresh S. Ramalingam et al.   Journal of Thoracic Oncology

Histone Deacetylase Inhibitor MS-275 Exhibits Poor Brain Penetration: Pharmacokinetic Studies of [11C]MS-275 using Positron Emission Tomography

(2009) Jacob M. Hooker et al.   ACS Chemical Neuroscience

A phase II multiple dose clinical trial of histone deacetylase inhibitor ITF2357 in patients with relapsed or progressive multiple myeloma

(2009) Monica Galli et al.   ANNALS OF HEMATOLOGY

Combined inhibition of DNA methylation and histone acetylation enhances gene re-expression and drug sensitivity in vivo

(2009) N Steele et al.   BRITISH JOURNAL OF CANCER

Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia

(2009) Kristie A. Blum et al.   BRITISH JOURNAL OF HAEMATOLOGY

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

(2009) Susan E. Bates et al.   BRITISH JOURNAL OF HAEMATOLOGY

Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862)

(2009) Deborah Bradley et al.   CANCER

Characterization of UGTs Active against SAHA and Association between SAHA Glucuronidation Activity Phenotype with UGT Genotype

(2009) R. M. Balliet et al.   CANCER RESEARCH

Phase I and pharmacokinetic study of vorinostat (suberoylanilide hydroxamic acid) in Japanese patients with solid tumors

(2009) Yutaka Fujiwara et al.   CANCER SCIENCE

Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma

(2009) Takashi Watanabe et al.   CANCER SCIENCE

A Single Supratherapeutic Dose of Vorinostat Does Not Prolong the QTc Interval in Patients with Advanced Cancer

(2009) P. N. Munster et al.   CLINICAL CANCER RESEARCH

Rational Combinations Using HDAC Inhibitors

(2009) M. Bots et al.   CLINICAL CANCER RESEARCH

Population Pharmacokinetics of Romidepsin in Patients with Cutaneous T-Cell Lymphoma and Relapsed Peripheral T-Cell Lymphoma

(2009) S. Woo et al.   CLINICAL CANCER RESEARCH

Clinical Studies of Histone Deacetylase Inhibitors

(2009) H. M. Prince et al.   CLINICAL CANCER RESEARCH

A phase 2 study of vorinostat in acute myeloid leukemia

(2009) E. W. Schaefer et al.   HAEMATOLOGICA

ORIGINAL ARTICLE: Solubilization of vorinostat by cyclodextrins

(2009) Y. Y. Cai et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Pharmacokinetics-pharmacodynamics and antitumor activity of mercaptoacetamide-based histone deacetylase inhibitors

(2009) Z. Konsoula et al.   MOLECULAR CANCER THERAPEUTICS

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma

(2008) M. Crump et al.   ANNALS OF ONCOLOGY

Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia

(2008) G. Garcia-Manero et al.   BLOOD

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor, MS-275, in Patients with Refractory Solid Tumors and Lymphomas

(2008) L. Gore et al.   CLINICAL CANCER RESEARCH

Evaluation of the Pharmacodynamic Effects of MGCD0103 from Preclinical Models to Human Using a Novel HDAC Enzyme Assay

(2008) C. Bonfils et al.   CLINICAL CANCER RESEARCH

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid Tumors

(2008) N. L. Steele et al.   CLINICAL CANCER RESEARCH

Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes

(2008) V. M. Klimek et al.   CLINICAL CANCER RESEARCH

Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma

(2008) L. Ellis et al.   CLINICAL CANCER RESEARCH

A Phase II Trial of Vorinostat (Suberoylanilide Hydroxamic Acid) in Metastatic Breast Cancer: A California Cancer Consortium Study

(2008) T. H. Luu et al.   CLINICAL CANCER RESEARCH

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

(2008) Peter Gimsing et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)

(2008) Robert P. Whitehead et al.   INVESTIGATIONAL NEW DRUGS

Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer

(2008) Johan Vansteenkiste et al.   INVESTIGATIONAL NEW DRUGS

Phase I Study of MGCD0103 Given As a Three-Times-Per-Week Oral Dose in Patients With Advanced Solid Tumors

(2008) Lillian L. Siu et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery ofN-(2-Aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an Orally Active Histone Deacetylase Inhibitor

(2008) Nancy Zhou et al.   JOURNAL OF MEDICINAL CHEMISTRY

MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo

(2008) M. Fournel et al.   MOLECULAR CANCER THERAPEUTICS

Histone acetylation and chromatin signature in stem cell identity and cancer

(2007) Vivek Shukla et al.   MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS